Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

Clinical Trial ID NCT00666588

Rank	Title	Journal	Year	PubWeight™‹?›
1	Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1.	Blood	2012	1.23
2	Cancerous inhibitor of protein phosphatase 2A determines bortezomib-induced apoptosis in leukemia cells.	Haematologica	2012	0.90
3	A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.	Pediatr Blood Cancer	2014	0.89
4	Novel agents for the treatment of childhood acute leukemia.	Ther Adv Hematol	2015	0.87
5	Immune-based therapeutics for pediatric cancer.	Expert Opin Biol Ther	2010	0.78
6	Advances in paediatric cancer treatment.	Transl Pediatr	2014	0.76
7	Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities.	World J Stem Cells	2016	0.76
8	Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.	J Hematol Oncol	2016	0.75